Clareo Health | Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of follicular lymphoma
Recurrent lymphoma after one or two qualifying therapy regimen(s)
Patients must not have progressed within 4 weeks of their last chemotherapy dose
Rituximab may have been used once as a single agent, in one continuous course of 4-8 weekly infusions (10-week period), or in combination with chemotherapy in a single prior treatment
Patients whose prior therapy includes rituximab must have had a 6 month or greater response duration following the rituximab-containing regimen.
Performance status of at least 70% on the Karnofsky Scale and an anticipated survival of at least three months
Adequate absolute neutrophil count and platelet count within 21 days of study entry without support of blood products/growth factors
Adequate renal function and adequate hepatic within 21 days of study entry
Measurable disease, with at least one lesion measuring \>/=2.0 cm x 2.0 cm by CT scan
Human Anti Mouse Antigen negative
Written informed consent prior to study entry
You may not be if
Histologic transformation to diffuse, large cell lymphoma.
History of more than one course of Rituximab
Disease limited to single lymph node or single group of nodes
Involvement of 25% of the intratrabecular marrow by bone marrow biopsy specimen.
Active infection requiring IV antibiotics at the time of study entry
New York Heart Association Class III/IV heart disease
Prior chemotherapy, biologic, radiation or steroid therapy for NHL within 8 weeks
Any prior radioimmunotherapy
Prior history of malignancy other than lymphoma (except for treated basal cell, squamous cell skin cancer, in situ cervical cancer, or other cancer that is disease-free for 5 years)
